Cited by 187Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsMultiple Sclerosis Research Studies

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial

ROG, D, NURMIKKO, T, YOUNG, C·2007·Clinical Therapeutics

DOI 10.1016/j.clinthera.2007.09.013

Open this paper in CoChat — free account

Abstract

Background Central neuropathic pain (CNP), pain initiated or caused by a primary lesion or dysfunction of the central nervous system, occurs in ~28% of patients with multiple sclerosis (MS). Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS.Objective The purpose of this extension was to establish long-term tolerability and effectiveness profiles for THC/CBD (Sativex (R), GW Pharmaceuticals plc, Salisbury, United Kingdom) oromucosal spray in CNP associated with MS.Methods This uncontrolled, open-label trial was an indefinite-duration extension of a previously reported 5-week randomized study in patients with MS and CNP. In the initial trial, patients were randomized to placebo or THC/CBD. Patients were only required to maintain their existing analgesia in the randomized study. In the open-label trial they could vary their other analgesia as required. All patients (placebo and THC/CBD) who completed the randomized trial commenced the open-label follow-up on THC/CBD (27 mg/mL: 25 mg/mL). Patients titrated their dosage, maintaining their existing analgesia. The primary end point of the trial was the number, frequency, and type of adverse events (AEs) reported by patients. Secondary end points included changes from baseline in 11-point numerical rating scale (NRS-11) neuropathic pain score, hematology and clinical chemistry test results, vital signs, trial drug usage, and intoxication visual analogue scale scores.Results Sixty-six patients were enrolled in the randomized trial; 64 (97%) completed the randomized trial and 63 (95%) entered the open-label extension (race, white, 100%; sex, male, 14 [22%]; mean [SD] age, 49 [8.4] years [range, 27-71 years[). The mean (SD) duration of open-label treatment was 463 (378) days (median, 638 days; range, 3-917 days), with 34 (54%) patients completing >1 year of treatment with THC/CBD and 28 (44%) patients completing the open-label trial with a mean (SD) duration of treatment of 839 (42) days (median, 845 days; range, 701-917 days). Mean NRS-11 pain scores in the final week of the randomized trial were 3.8 in the treatment group and 5.0 in the placebo group. In the 28 (44%) patients who completed the 2-year follow up, the mean (SD) NRS-11 pain score in the final week of treatment was 2.9 (2.0) (range, 0-8.0). Fifty-eight (92%) patients experienced > or =1 treatment-related AE. These AEs were rated by the investigator as mild in 47 (75%) patients, moderate in 49 (78%), and severe in 32 (51%). The most commonly reported AEs were dizziness (27%), nausea (18 %), and feeling intoxicated (11%). Two treatment-related serious AEs (ventricular bigeminy and circulatory collapse) were judged to be treatment-related. Both serious AEs occurred in the same patient and resolved completely following a period of discontinuation. Eleven (17%) patients experienced oral discomfort, 4 persistently. Regular oral examinations revealed that 7 (11%) patients developed white buccal mucosal patches and 2 (3%) developed red buccal mucosal patches; all cases were deemed mild and resolved. Seventeen (25%) patients withdrew due to AEs. The mean number of sprays and patients experiencing intoxication remained stable throughout the follow-up trial.Conclusions THC/CBD was effective, with no evidence of tolerance, in these select patients with CNP and MS who completed approximately 2 years of treatment (n = 28). Ninety-two percent of patients experienced an AE, the most common of which were dizziness and nausea. The majority of AEs were deemed to be of mild to moderate severity by the investigators.

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2007.09.013

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms
Merskey, H. (1994) · Medical Entomology and Zoology · Cited by 3,362
The measurement of clinical pain intensity: a comparison of six methods
Jensen, M. P., Karoly, P., & Braver, S. (1986) · Pain · doi:10.1016/0304-3959(86)90228-9 · Cited by 3,275
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus A Randomized Controlled Trial
Bačkonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,529
Gabapentin for the Treatment of Postherpetic Neuralgia A Randomized Controlled Trial
Rowbotham, M. C. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,418
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,337
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M. L., Hansson, P. T., Jensen, T. S., Nurmikko, T. J., Sampaio, C., Sindrup, S. H., & Wiffen, P. J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 877
Development and preliminary validation of a pain measure specific to neuropathic pain
Galer, B. S., & Jensen, M. (1997) · Neurology · doi:10.1212/wnl.48.2.332 · Cited by 778

Show all 28 references

Sorted by citations

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
“Adverse events (dizziness, dry mouth, sedation, fatigue, gastrointestinal effects, oral discomfort) were reported by 90% of patients in longterm extension study (up to 3 years), but no tolerance was observed [74].”
BackgroundSelf-citation
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
“Apart from MS spasticity (263), Sativex is effective against neuropathic pain in MS patients, with no evidence of tolerance up to 2 yr of treatment (739).”
Background
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
“The safety and tolerability of nabiximols long-term use in different conditions (cancer pain, spasticity and neuropathic pain in MS patients) has been studied in a series of trials of up to 2 years duration (Wade et al., 2006; Rog et al., 2007; Johnson et al., 2013; Serpell et al., 2013).”
Background
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective
Cooper, Z. D., & Craft, R. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.140 · Cited by 369
“…pain (Issa et al, 2014; Ware et al, 2015), chronic neuropathic pain (Karst et al, 2003), multiple sclerosis-associated pain (Svendsen et al, 2004; Rog et al, 2007), HIV-associated neuropathy (Abrams et al, 2007; Ellis et al, 2009), postoperative pain (Buggy et al, 2003), chronic headache (Pini…”
Background
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
“This effect was maintained without signs of tolerance in an open-label, uncontrolled two year extension that recruited participants from the previous trial (Rog et al., 2007).”
Background
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298
“A 2-year, open-label follow-up study showed continued effectiveness with THC/CBD spray, and no evidence of tolerance was seen in the 28 patients who completed the study [21].”
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 308
“…performed have shown that Sativex has beneﬁcial effects on spasticity, mobility, bladder function, and pain in MS patients, and is well tolerated 22,25,28,31,168–175 ; however, there has been little focus on the neuroprotective and immunosuppressive effects of THC:CBD mixtures in MS, and so it is…”
Pharmacology of Medical Cannabis
Amin, M. R., & Ali, D. W. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21737-2_8 · Cited by 313
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283
Cannabinoids and Epilepsy
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 292
Medical Use of Cannabinoids
Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 287
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
Baron, E. P. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 268
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1177-4 · Cited by 229
“CBD is well tolerated in vivo during acute and chronic systemic administration [14–18], and cannabinoids are already being used in clinical trials for purposes unrelated to their antitumor activity [19, 20].”
Background
Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
Iuvone, T., Esposito, G., Filippis, D. D., Scuderi, C., & Steardo, L. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00065.x · Cited by 217
“[92], offering the rationale for performing randomized, controlled trials of Cannabisbased medicine in MS-associated symptomatology.”
Background
A mechanism-based classification of pain in multiple sclerosis
Truini, A., Barbanti, P., Pozzilli, C., & Cruccu, G. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6579-2 · Cited by 215
Review of the neurological benefits of phytocannabinoids
Maroon, J. C., & Bost, J. (2018) · Surgical Neurology International · doi:10.4103/sni.sni_45_18 · Cited by 219
“[22] A meta-analysis in 2007 reported that CB receptor-based medications were superior to placebo in the treatment of MS-related neuropathic pain.[58,78,93,94,121] This analysis evaluated 18 studies that included Sativex® (n = 196), CBD (n = 41), and dronabinol, Marinol®, Δ9-THC only (n = 91).”
Method
A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E. (2014) · European Journal of Pain · doi:10.1002/j.1532-2149.2013.00445.x · Cited by 197
“© 2014 European Pain Federation - EFIC® Eur J Pain 18 (2014) 999–1012 1009 ports the consistent improvements in sleep seen in other clinical studies of this drug (Rog et al., 2005, 2007; Attal et al., 2006; Nurmikko et al., 2007).”
Background
Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids
Kohli, D. R., Li, Y., Khasabov, S. G., Gupta, P., Kehl, L. J., Ericson, M. E., Nguyen, J., Gupta, V., Hebbel, R. P., Simone, D. A., et al. (2010) · Blood · doi:10.1182/blood-2010-01-260372 · Cited by 192
The endocannabinoid system as a target for the treatment of neurodegenerative disease
Scotter, E. L., Abood, M. E., & Glass, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00735.x · Cited by 188
“The large majority of adverse events reported in trials have been mild to moderate and the use of Sativex has not been correlated with any decline in cognitive measures in MS patients (Rog et al., 2007; Aragona et al., 2009; reviewed in Wade et al., 2006; Smith, 2007).”
Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0862-2 · Cited by 188
Pain and Multiple Sclerosis: Pathophysiology and Treatment
Solaro, C., Trabucco, E., & Uccelli, M. M. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0320-5 · Cited by 182
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions
Thompson, A. J., Toosy, A., & Ciccarelli, O. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70249-0 · Cited by 179
Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
Marcu, J. P., Christian, R. T., Lau, D., Zielinski, A. J., Horowitz, M. P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D. H., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0407 · Cited by 174
“Published Online First on January 6, 2010 as 10.1158/1535-7163.MCT-09-0407 human clinical trials (20, 22, 23 ).”
Influential
An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174
“While submucosal delivery of tetrahydrocannabis and cannabidiol [36,37] has been effective in management of NeP in patients with multiple sclerosis, a study in patients with DPN-associated NeP failed to determine efficacy for cannabinoids [40].”
BackgroundResult
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
Kavia, R., Ridder, D. J. M. K. D., Constantinescu, C. S., Stott, C., & Fowler, C. J. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510378020 · Cited by 173
Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule‐1
Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., Borchert, P., Schmuhl, E., Linnebacher, M., & Hinz, B. (2011) · The FASEB Journal · doi:10.1096/fj.11-198184 · Cited by 169
“Besides its beneficial effects on inflammation, pain, and spasticity when used for the treatment of multiple sclerosis (17), CBD has been reported to exert inhibitory effects on tumor angiogenesis (18) and metastasis (12, 13, 19) and to induce cancer cell apoptosis (20, 21).”
Background
The analgesic potential of cannabinoids.
Elikottil, M., Gupta, M., & Gupta, P. (2018) · Journal of Opioid Management · doi:10.5055/jom.2009.0034 · Cited by 141
“A 2 yr open label study as a follow up of this trial using Sativex® in 63 MS patients showed it to be effective in decreasing pain, however less than half of the subjects completed the trial [99].”
Method
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence
Prud'homme, M., Cata, R., & Jutras‐Aswad, D. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s25081 · Cited by 133
Current Management of Pain Associated with Multiple Sclerosis
Pöllmann, W., & Feneberg, W. W. (2008) · CNS Drugs · doi:10.2165/00023210-200822040-00003 · Cited by 131
Medical marijuana for cancer
Kramer, J. L. (2014) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21260 · Cited by 138
“Nabiximols did improve central neuropathic pain from multiple sclerosis in another randomized trial,(78) and pain relief persisted in the open-label continuation study.(79) This drug was not better than placebo in the treatment of painful diabetic peripheral neuropathy in one study.”
Background
Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental Autoimmune Hepatitis Following Activation of TRPV1 Receptors by Cannabidiol
Hegde, V. L., Nagarkatti, P. S., & Nagarkatti, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018281 · Cited by 129
A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1441-0 · Cited by 128
Therapeutic potential of cannabis in pain medicine
Hosking, R., & Zajicek, J. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen119 · Cited by 124
Therapeutic potential of cannabinoid medicines
Robson, P. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1529 · Cited by 126
Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models
Khan, N., & Smith, M. T. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0195-3 · Cited by 126
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-236 · Cited by 120
Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts
Kogan, N. M., Melamed, E., Wasserman, E., Raphael-Mizrahi, B., Breuer, A., Stok, K. S., Sondergaard, R. E., Escudero, A. V. V., Baraghithy, S., Attar-Namdar, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2513 · Cited by 115
“A combination of THC and CBD is not only a hallmark of cannabis, but a mixture of equal amounts of these ingredients has been recommended for therapeutic use.((6)) Hence, experiment 2 tested their combined effect on the biomechanics of the healing bone.”
Background
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
Serpell, M. G., Notcutt, W. G., & Collin, C. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6634-z · Cited by 113
Cannabis and Cannabinoids for Chronic Pain
Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 115
Review on clinical studies with cannabis and cannabinoids 2005-2009
Hazekamp, A., & Grotenhermen, F. (2010) · Cited by 110
Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain
Rock, E. M., Limebeer, C. L., & Parker, L. A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5034-1 · Cited by 107
Role of Cannabinoids in Multiple Sclerosis
Zajicek, J., & Apostu, V. I. (2011) · CNS Drugs · doi:10.2165/11539000-000000000-00000 · Cited by 106
“The 2-year open-label follow-up study found that nabiximols was effective, with no evidence of tolerance in the 28 patients who completed the study.([99]) Results from the CAMS study again demonstrated significant patient-reported effects on pain with both dronabinol and Cannador using category rating scales.”
Method
The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration
Gowran, A., Noonan, J., & Campbell, V. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00195.x · Cited by 109
“Furthermore, Sativex, an oral-mucosal spray containing a 1:1 ratio of 9-THC and CBD, has antispasmodic and analgesic properties with efficacy in MS patients [69].”
Background
Endocannabinoids: A unique opportunity to develop multitarget analgesics
Maione, S., Costa, B., & Marzo, V. D. (2013) · Pain · doi:10.1016/j.pain.2013.03.023 · Cited by 104
“for the treatment of spasticity in multiple sclerosis in several countries, but, since 2007 in Canada, also against neuropathic pain in multiple sclerosis and cancer pain [63,67].”
Background
Management of pain in multiple sclerosis: a pharmacological approach
Solaro, C. M., & Uccelli, M. M. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.120 · Cited by 97
The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation
Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165771 · Cited by 103
Sex-dependent effects of cannabis-induced analgesia
Cooper, Z. D., & Haney, M. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.08.001 · Cited by 104
“…M anuscript A uthor M anuscript A uthor M anuscript analysis (Noyes et al., 1975; Karst et al., 2003; Naef et al., 2003; Svendsen et al., 2004; Abrams et al., 2007; Nurmikko et al., 2007; Rog et al., 2007; Wilsey et al., 2008 and 2013; Ware et al., 2010; Issa et al., 2014; Wallace et al., 2015).”
Background
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
Sastre‐Garriga, J., Vila, C., Clissold, S. P., & Montalbán, X. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.47 · Cited by 91
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 91
Decrease of Plasminogen Activator Inhibitor-1 May Contribute to the Anti-Invasive Action of Cannabidiol on Human Lung Cancer Cells
Ramer, R., Rohde, A., Merkord, J., Rohde, H., & Hinz, B. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0219-2 · Cited by 91
“Besides the beneficial effects of cannabidiol in the treatment of pain and spasticity associated with multiple sclerosis ( 17 ), several reports demonstrated anti-metastatic (18,19), proapoptotic (20–22), and anti-angiogenic (23) effects of this cannabinoid.”
Background
Medical Cannabis for Neuropathic Pain
Lee, G., Grovey, B., Furnish, T. J., & Wallace, M. S. (2018) · Current Pain and Headache Reports · doi:10.1007/s11916-018-0658-8 · Cited by 87
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain
Hoggart, B., Ratcliffe, S. H., Ehler, E., Simpson, K. H., Hovorka, J., Lejčko, J., Taylor, L., Lauder, H., & Serpell, M. G. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7502-9 · Cited by 87
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Cooper, Z. D., Comer, S. D., & Haney, M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.97 · Cited by 85
Cannabidiol-Δ 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity
Britch, S. C., Wiley, J. L., Yu, Z., Clowers, B. H., & Craft, R. M. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.046 · Cited by 83
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies
Zeraatkar, D., Cooper, M. A., Agarwal, A., Vernooij, R. W. M., Leung, G., Loniewski, K., Dookie, J., Ahmed, M. M., Hong, B. Y., Hong, C. J. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054282 · Cited by 87
Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen: Eine systematische Übersichtsarbeit von randomisierten, kontrollierten Studien
Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0089-y · Cited by 80
Medicinal herbs in the treatment of neuropathic pain: a review.
Forouzanfar, F., & Hosseinzadeh, H. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.24026.6021 · Cited by 80
“352 improve of neuropathic pain in multiple sclerosis (MS) in adults (97).”
BackgroundInfluential
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
Ueberall, M. A. (2020) · Journal of Pain Research · doi:10.2147/jpr.s240011 · Cited by 82
“There was no evidence of tolerance during up to 2 years’ treatment.(88) A larger placebo-controlled trial of add-on THC:CBD oromucosal spray (nabiximols) conducted in 339 patients”
Background
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands
Davis, M. P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918603 · Cited by 81
“dizziness, nausea, feelings of intoxication and confusion, which has been largely attributed to activation of supraspinal cannabinoid receptors [1,9].”
Background
An Open‐Label Comparison of Nabilone and Gabapentin as Adjuvant Therapy or Monotherapy in the Management of Neuropathic Pain in Patients with Peripheral Neuropathy
Bestard, J. A., & Toth, C. C. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00427.x · Cited by 76
Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice
Rahimi, A., Faizi, M., Talebi, F., Noorbakhsh, F., Kahrizi, F., & Naderi, N. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.030 · Cited by 81
“Cannabinoid drugs such as delta-9-tetrahydrocannabinol (D9-THC) are now authorized as a treatment for the pain and spasticity in MS, but these medications may also have psychoactive effects (Rog et al., 2005, 2007).”
Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications
Ford, T. C., Hayley, A. C., Downey, L. A., & Parrott, A. C. (2017) · Current Drug Abuse Reviews · doi:10.2174/1874473710666170712113042 · Cited by 80
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Multiple Sclerosis-Related Central Pain Disorders
Nurmikko, T. J., Gupta, S., & Maclver, K. (2010) · Current Pain and Headache Reports · doi:10.1007/s11916-010-0108-8 · Cited by 75
“However, the attrition rate was high, with 46% withdrawing during the first year and a further 12% the following year [ 24 ].”
Background
Symptomatic treatment and management of multiple sclerosis
Toosy, A., Ciccarelli, O., & Thompson, A. J. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00023-6 · Cited by 79
Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis
Russo, M., Naro, A., Leo, A., Sessa, E., D’Aleo, G., Bramanti, P., & Calabrò, R. S. (2016) · Pain Medicine · doi:10.1093/pm/pnv080 · Cited by 72
Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain
Blanton, H. L., Brelsfoard, J., Deturk, N., Pruitt, K., Narasimhan, M., Morgan, D. J., & Guindon, J. (2019) · Drugs · doi:10.1007/s40265-019-01132-x · Cited by 71
“Three clinical trials found nabiximols (Sativex, 1:1 THC:CBD) to be effective in patients with neuropathic pain of peripheral origin [115]; central neuropathic pain, mainly spasticity associated with MS [118]; and HIV-DSPN [116].”
Background
Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey of Randomized-controlled Trial Results
Aggarwal, S. K. (2013) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31824c5e4c · Cited by 62
Therapeutic benefits of cannabis: a patient survey.
Webb, C. W., & Webb, S. M. (2014) · Europe PMC (PubMed Central) · Cited by 61
Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada
Cahill, S. P., Lunn, S. E., Diaz, P. L., & Page, J. E. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.626853 · Cited by 56
Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs
Parmar, J. R., Forrest, B. D., & Freeman, R. A. (2015) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2015.09.002 · Cited by 57
Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey
Weber, J., Schley, M. T., Casutt, M., Gerber, H., Schuepfer, G., Rukwied, R., Schleinzer, W., Ueberall, M. A., & Konrad, C. J. (2009) · Anesthesiology Research and Practice · doi:10.1155/2009/827290 · Cited by 56
Phytocannabinoids and Endocannabinoids
Fišar, Z. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902010051 · Cited by 57
Differential Drug–Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy
Brents, L. K., Zimmerman, S. M., Saffell, A., Prather, P. L., & Fantegrossi, W. E. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206003 · Cited by 55
“…commonly reported by users of the clinically available CB1R agonists dronabinol (Marinol; AbbVie Inc., North Chicago, IL) and nambiximols (Sativex; GW Pharmaceuticals, Salisbury, UK): difficulty in performing simple, everyday tasks that could otherwise be performed with ease (Rog et al., 2007).”
Background
“Disease modifying nutricals” for multiple sclerosis
Schmitz, K., Barthelmes, J., Stolz, L., Beyer, S., Diehl, O., & Tegeder, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.015 · Cited by 55
The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis
Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Inflammation Research · doi:10.1007/s00011-020-01341-1 · Cited by 55
Single dose delta‐9‐tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability
de Vries, M., Van Rijckevorsel, D. C. M., Vissers, K. C. P., Wilder‐Smith, O. H. G., & Van Goor, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12811 · Cited by 54
Pharmacological Management of Pain in Patients with Multiple Sclerosis
Solaro, C., & Uccelli, M. M. (2010) · Drugs · doi:10.2165/11537930-000000000-00000 · Cited by 57
Discriminating the Effects of Cannabis sativa and Cannabis indica: A Web Survey of Medical Cannabis Users
Pearce, D. D., Mitsouras, K., & Irizarry, K. J. L. (2014) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2013.0190 · Cited by 46
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
Rodrigues, R. S., Lourenço, D. M., Paulo, S. L., Mateus, J. M., Ferreira, M. F., Mouro, F. M., Moreira, J. B., Ribeiro, F. F., Sebastião, A. M., & Xapelli, S. (2019) · Molecules · doi:10.3390/molecules24071350 · Cited by 47
Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Galal, A. M., Slade, D., Gul, W., El‐Alfy, A. T., Ferreira, D., & ElSohly, M. A. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909788453031 · Cited by 44
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
Turri, M., Teatini, F., Donato, F., Zanette, G., Tugnoli, V., Deotto, L., Bonetti, B., & Squintani, G. M. (2018) · Medicines · doi:10.3390/medicines5030059 · Cited by 43
“Consistent with previous studies [31,32], our results show that Sativex® therapy is effective for relieving pain, as seen in the significant reduction in the NRS scores.”
Result
Treating pain in multiple sclerosis
Truini, A., Galeotti, F., & Cruccu, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.607162 · Cited by 42
“Despite this beneficial effect and the lack of tolerance in that study, 92% of patients experienced adverse events and 46% withdrew during the first year [77].”
Background
Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Suryadevara, U., Bruijnzeel, D. M., Nuthi, M., Jagnarine, D. A., Tandon, R., & Bruijnzeel, A. W. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161101095325 · Cited by 43
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
Vasincu, A., Rusu, R.-N., Ababei, D. C., Larion, M., Bild, W., Stanciu, G. D., Solcan, C., & Bild, V. (2022) · Biology · doi:10.3390/biology11030440 · Cited by 44
“for the next 2 years, and it was observed that the effect was maintained, with no signs of tolerance [198].”
Background
Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review
Farzaei, M. H., Shahpiri, Z., Bahramsoltani, R., Moghadamnia, M., Najafi, F., & Rahimi, R. (2017) · CNS Drugs · doi:10.1007/s40263-017-0466-4 · Cited by 41
Characterization of the Solutol® HS15/water phase diagram and the impact of the Δ9-tetrahydrocannabinol solubilization
Murgia, S., Fadda, P., Colafemmina, G., Angelico, R., Corrado, L., Lazzari, P., Monduzzi, M., & Palazzo, G. (2012) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2012.08.068 · Cited by 40
Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
McDonough, P., McKenna, J. P., McCreary, C., & Downer, E. J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.08.007 · Cited by 55
Cannabis-based medicines in multiple sclerosis – A review of clinical studies
Rog, D. J. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.03.009 · Cited by 39
“%) entered the openlabel extension (Rog et al., 2007) of which 14 (22”
Background
Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases
Abd‐Nikfarjam, B., Dolati‐Somarin, A., Rahimi, V. B., & Askari, V. R. (2023) · BioFactors · doi:10.1002/biof.1936 · Cited by 37
Polypharmacology Shakes Hands with Complex Aetiopathology
Brodie, J., Marzo, V. D., & Guy, G. W. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.010 · Cited by 38
Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non‐cannabinoid receptor‐mediated mechanisms
Maione, S., Morera, E., Marabese, I., Ligresti, A., Luongo, L., Ortar, G., & Marzo, V. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.308 · Cited by 33
“Furthermore, the use of D(9)-tetrahydrocannabinol together with a non-psychotropic cannabinoid, cannabidiol, seems to reduce the typical unwanted side effects of the former compound and increase the analgesic efficacy in both neuropathic pain from multiple sclerosis and cancer pain (Russo and Guy, 2006; Iskedjian et a…”
Background
Nutraceuticals: A source of benefaction for neuropathic pain and fibromyalgia
Mishra, G., Singh, P. N. D., Molla, M., Yimer, Y. S., Ewunetie, A., Tadesse, T. Y., Ayele, T. M., & Kefale, B. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105260 · Cited by 32

Authors: ROG, D., NURMIKKO, T., & YOUNG, C.
Affiliations: Walton Centre (GB)
ORCID: ROG, D
NURMIKKO, T
YOUNG, C
Venue: Clinical Therapeutics
Publisher: Elsevier BV
Published: 2007-09
Volume: 29
Issue: 9
Pages: 2068-2079
ISSN: 0149-2918 (ISSN-L)
DOI: 10.1016/j.clinthera.2007.09.013
OpenAlex: W1996712837
Cited by: 187
References: 28
Citations by year: 2026: 3 · 2025: 2 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 14 · 2017: 13 · 2016: 8 · 2015: 10 · 2014: 13 · 2013: 14 · 2012: 15
FWCI: 9.08
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Clinical Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: Bayer Corporation
GW Pharmaceuticals
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords: central pain, multiple sclerosis, oromucosal spray, Sativex, long-term tolerability, adverse events, endocannabinoid system, pain management, cannabis-based medicines, poisoning, analgesia, vital signs, drug use, open-label extension
MeSH terms: Administration, Oral, Administration, Sublingual, Adult, Aerosols, Analgesics, Opioid, Cannabidiol, Central Nervous System Diseases, Drug Combinations, Female, Humans, Male, Middle Aged, Mouth Mucosa, Multiple Sclerosis, Pain, Plant Extracts, Dronabinol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks